至收盘时，科创综指收于1602.11点，跌幅1.84%，总成交额约1856亿元，总成交额较上一交易日微幅缩 量。科创50指数报1361.23点，跌幅2.72%，总成交额约613亿元，成分股总成交额较上一交易日小幅缩 量。 当日，科创板个股涨少跌多，394股收跌，占比约66.55%。细分领域中，华盛锂电、中信博、海目星等 锂电、新能源产业链相关股仍相对强势，佰维存储、普冉股份等存储股大跌，带动半导体产业链相关股 多有下跌，对指数形成拖累。 本周（11月10日至14日），科创综指累计下跌2.30%，科创50指数累计下跌3.85%。 转自：新华财经 新华财经北京11月14日电（罗浩）科创板两大股指14日早间均显著低开，两股指盘初波动反弹，科创综 指跌幅一度收窄至0.14%，科创50指数跌幅仅收窄至0.61%，此后两股指持续震荡下行，午后跌幅扩 大，收盘时均大幅下跌。 经新华财经统计，11月14日，科创板592股平均跌幅0.88%，平均换手率2.77%，合计成交额1856.22亿 元，平均振幅为3.95%。 编辑：王媛媛 成交额方面，中芯国际成交额94.33亿元，位居首位；*ST观典成交额1167.06万元，位居末位 ...

Core Viewpoint - The pharmaceutical sector is experiencing active trading, with innovative drugs and biovaccines showing strong performance, indicating a positive outlook for the industry through 2026 [1] Industry Summary - The pharmaceutical sector has seen significant stock price increases, with companies like Chengda Pharmaceutical, Kangzhi Pharmaceutical, and Haichen Pharmaceutical reaching a 20% limit up, while others like Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also hit the limit up [1] - CITIC Securities forecasts that the investment trend in the pharmaceutical industry will continue to be driven by the concentration of innovation in Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices, leading to a stable domestic market environment [1] - The industry is expected to return to a market pricing system based on clinical value and demand, which will contribute to a stable and continuous growth trend in the performance of listed companies [1] Investment Strategy - The pharmaceutical industry is recommended for continued overweight positioning, with suggested investment themes for 2026 including: 1. Innovation-driven and internationalization, focusing on companies that are innovating and expanding internationally in a favorable domestic policy environment [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research that can replace imports due to geopolitical risks [1] 3. New policies and new opportunities, targeting companies benefiting from optimized procurement, medical insurance payment reforms, consumption stimulus policies, and state-owned enterprise reforms [1]

Group 1: A-Share Market Performance - The A-share market experienced overall low-level fluctuations on November 14, with major indices declining. The Shanghai Composite Index fell by 0.16%, the Shenzhen Component Index decreased by 1.10%, and the ChiNext Index dropped by 1.74% [4][10] - The real estate sector showed resilience, with stocks like Rongsheng Development and Huaxia Happiness hitting the daily limit [9][10] - The pharmaceutical sector saw significant gains, with multiple stocks such as Shuyou Pingmin, Kangzhi Pharmaceutical, and Haichen Pharmaceutical reaching the daily limit of 20% [6][9] Group 2: Pharmaceutical Sector Insights - The pharmaceutical and biotechnology sector was notably active, with several stocks hitting the daily limit. Specific stocks included Shuyou Pingmin (+20.03%), Kangzhi Pharmaceutical (+20.00%), and Haichen Pharmaceutical (+19.99%) [6][7] - A report from CITIC Securities highlighted a positive outlook for the pharmaceutical industry through 2026, driven by innovation and supportive policies. The report suggests that the industry is expected to return to a market pricing system based on clinical value and demand [9] Group 3: Hong Kong Market Performance - The Hong Kong market also faced declines, with the Hang Seng Index dropping over 1%. Notable declines were seen in tech stocks, including Baidu and JD.com [12] - However, hydrogen energy-related stocks surged, with Reshape Energy experiencing a peak increase of over 60% during trading [11][12][15] - The recent policy from the National Energy Administration aimed at promoting the integration of coal and new energy has contributed to the rise in hydrogen energy stocks [15]

Group 1: A-Share Market Performance - The A-share market experienced overall low-level fluctuations on November 14, with major indices declining. The Shanghai Composite Index fell by 0.16%, the Shenzhen Component Index decreased by 1.10%, and the ChiNext Index dropped by 1.74% [4] - The real estate sector showed resilience, with stocks like Rongsheng Development and Huaxia Happiness hitting the daily limit [9] - The pharmaceutical sector saw significant gains, with multiple stocks such as Shuyupingmin, Kangzhi Pharmaceutical, and Haichen Pharmaceutical reaching the daily limit of 20% [6][9] Group 2: Pharmaceutical Sector Insights - The pharmaceutical and biotechnology sector was notably active, with several stocks hitting the daily limit. Specific stocks included Shuyupingmin (+20.03%), Kangzhi Pharmaceutical (+20.00%), and Haichen Pharmaceutical (+19.99%) [6][7] - A report from CITIC Securities highlighted a positive outlook for the pharmaceutical industry through 2026, driven by innovation and supportive policies. The report suggests that the industry is expected to return to a market pricing system based on clinical value and demand [9] Group 3: Hong Kong Market Performance - The Hong Kong market also faced declines, with the Hang Seng Index dropping over 1%. Notable declines were seen in tech stocks, including Baidu and JD.com [12] - However, hydrogen energy-related stocks surged, with Reshape Energy experiencing a peak increase of over 60% during trading [11][12] - Other hydrogen energy stocks, such as Guofu Hydrogen Energy and Guohong Hydrogen Energy, also saw significant gains, with increases of over 26% and 10%, respectively [15]

Group 1: Pharmaceutical Sector Performance - The pharmaceutical stocks in the A-share market experienced a significant surge despite the overall market downturn, with multiple stocks hitting the daily limit up [1][6][9] - Notable performers included Shuyupingmin (涨幅 +20.03%), Kangzhi Pharmaceutical (涨幅 +20.00%), and Haichen Pharmaceutical (涨幅 +19.99%) [7][6] - The medical and health industry is expected to maintain a stable growth trend, driven by innovation and supportive policies, with a focus on clinical value and demand-oriented pricing [9] Group 2: Real Estate Sector Insights - The real estate sector showed resilience, with several stocks such as Rongsheng Development and Huaxia Happiness hitting the daily limit up, despite a broader market decline [1][10] - National statistics indicated a 14.7% year-on-year decline in real estate development investment for the first ten months of 2025, with residential investment down by 13.8% [10] Group 3: Hydrogen Energy Stocks in Hong Kong - In the Hong Kong market, hydrogen-related stocks saw substantial gains, with Reshape Energy rising over 60% during trading [3][11] - The surge in hydrogen stocks is attributed to recent government policies promoting the integration of coal and new energy, which emphasizes technological innovation and development in the hydrogen sector [14]

Market Overview - A-shares experienced overall low-level fluctuations on November 14, with major indices declining. The Shanghai Composite Index fell by 0.16%, the Shenzhen Component Index dropped by 1.10%, and the ChiNext Index decreased by 1.74% [2][6] - The Hong Kong market also saw a decline, with the Hang Seng Index dropping over 1% [10][11] Sector Performance Real Estate Sector - The real estate sector showed strength, with a peak increase of over 1.6%. Stocks such as Rongsheng Development, Yingxin Development, and Huaxia Happiness reached their daily limit [6] - National statistics revealed that from January to October 2025, real estate development investment was 73,563 billion, a year-on-year decrease of 14.7%. Residential investment was 56,595 billion, down 13.8% [6] Pharmaceutical Sector - The pharmaceutical and biotechnology sector was notably active, with several stocks hitting their daily limit. Stocks like Shuyupingmin, Kangzhi Pharmaceutical, and Haichen Pharmaceutical saw increases of around 20% [2][3] - A report from CITIC Securities highlighted that the medical health industry is expected to maintain a stable growth trend, driven by innovation and supportive policies, suggesting a continued overweight in the pharmaceutical sector [5] Banking Sector - The banking sector performed well, with several banks like Industrial Bank and Bank of China seeing increases of over 2% [7] Hydrogen Energy Sector - In the Hong Kong market, multiple hydrogen energy-related stocks surged, with Reshape Energy experiencing a peak increase of over 60%. The company focuses on hydrogen technology and has developed various hydrogen production equipment [12][14] - National policies promoting the integration of coal and new energy are expected to support the hydrogen energy sector's growth [12]

New Stock Issuance - Cash option declaration period for Hangzhou Steam Turbine (200771) is from November 19 to November 25, 2025[1] - Acquisition request period for Hailianxun (300277) is from November 12 to November 18, 2025[1] Trading Alerts - Severe abnormal fluctuation reported for Haike Xinyuan (301292) on November 11, 2025[1] - Abnormal fluctuation noted for ST Yuancheng (603388) on November 11, 2025[1] Company Announcements - Announcement for Tianji Co., Ltd. (002759) on November 13, 2025[1] - Announcement for Huatong Technology (688109) on November 13, 2025[1] Other Notable Events - ST Meigu (000615) reported on November 13, 2025[1] - ST Zhongdi (000609) reported on November 13, 2025[1]

Core Insights - The total margin financing balance on the STAR Market decreased by 0.87 billion yuan to 258.26 billion yuan as of November 12, marking a continuous decline for four trading days [1][2] - The highest margin financing balance is held by Cambrian, with a balance of 14.645 billion yuan, followed by SMIC and Haiguang Information with balances of 13.756 billion yuan and 8.060 billion yuan respectively [1][2] - In terms of margin trading, 234 stocks saw an increase in financing balance, while 352 stocks experienced a decrease [1][2] Margin Financing Summary - The total margin financing balance is 258.26 billion yuan, down by 0.87 billion yuan from the previous trading day [1] - The highest margin financing stocks include: - Cambrian: 14.645 billion yuan - SMIC: 13.756 billion yuan - Haiguang Information: 8.060 billion yuan [1] - Notable increases in financing balance: - Magv Technology: +41.85% - Jindike: +34.50% - Yuanjie Technology: +20.74% [1][2] - Significant decreases in financing balance: - Wanrun New Energy: -25.13% - Elon Technology: -17.69% - XGIMI Technology: -15.33% [1][2] Margin Short Selling Summary - The total margin short selling balance is 0.899 billion yuan, down by 19.8591 million yuan from the previous trading day [1][2] - The highest margin short selling stocks include: - Haiguang Information: 0.039 billion yuan - Cambrian: 0.031 billion yuan - SMIC: 0.028 billion yuan [2] - Notable increases in short selling balance: - Foxit Software: +177.52% - Yirui Technology: +149.76% - Weimaisi: +76.58% [2] - Significant decreases in short selling balance: - Chengdu Xian Dao: -74.75% - Zhenhua Wind Power: -58.62% - Liyuanheng: -58.37% [2]

11月12日，金迪克跌11.09%，成交额3.33亿元。两融数据显示，当日金迪克获融资买入额3192.22万 元，融资偿还1929.68万元，融资净买入1262.54万元。截至11月12日，金迪克融资融券余额合计4922.39 万元。 融资方面，金迪克当日融资买入3192.22万元。当前融资余额4922.39万元，占流通市值的1.80%，融资 余额超过近一年90%分位水平，处于高位。 融券方面，金迪克11月12日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，江苏金迪克生物技术股份有限公司位于江苏省泰州市郁金路12号，成立日期2008年12月29 日，上市日期2021年8月2日，公司主营业务涉及专注于人用疫苗研发、生产、销售的生物制药企业。主 营业务收入构成为：疫苗产品100.00%。 截至9月30日，金迪克股东户数4319.00，较上期减少4.55%；人均流通股28525股，较上期增加4.77%。 2025年1月-9月，金迪克实现营业收入7465.76万元，同比增长91.93%；归母净利润 ...

New Stock Issuance - The stock code 300277 (Hai Lian Xun) has a subscription period for acquisition rights from November 12 to November 18, 2025[1] - Stock code 688353 (Hua Sheng Lithium) reported severe abnormal fluctuations on November 11, 2025[1] - Stock code 603122 (He Fu China) has an announcement dated November 8, 2025[1] Trading Alerts - Stock code 601888 (China Zhong Mian) has an announcement dated November 12, 2025[1] - Stock code 600537 (Yi Jing Guang Dian) has an announcement dated November 12, 2025[1] - Stock code 688028 (Wo Er De) has an announcement dated November 12, 2025[1] Abnormal Fluctuations - Stock code 600815 (Xia Gong Co.) reported abnormal fluctuations on November 6, 2025[2] - Stock code 603557 (ST Qi Bu) reported abnormal fluctuations on November 7, 2025[3] - Stock code 002478 (Chang Bao Co.) reported abnormal fluctuations on November 7, 2025[3]